Author: Per Lundström
Posts by Per Lundström
New publication on crovalimab’s pharmacokinetics and exposure–response in PNH trials
Karam Alali shares his experience of Uppsala Pharmacometric Summer School
The 2025 Uppsala Pharmacometrics Summer School (UPSS) is now open for applications. More than just a learning opportunity, UPSS offers participants the chance to connect with peers and gain practical skills in pharmacometrics. Karam Alali, a Ph.D. student and 2024 UPSS participant, attended the program with the support of a travel grant provided by Pharmetheus, which made his participation possible.
“Values are not just external slogans, they need to be lived”
New publication: A tutorial on pharmacometric Markov models
“I’m not just creating a model, I’m trying to save lives”
Lourdes Cucurull-Sanchez joins Pharmetheus as Scientific Lead for the Quantative Systems Pharmacology (QSP) platform
She brings extensive experience from several positions from large companies within drug development, and has made strong scientific contributions through her work within clinical pharmacology. The addition strengthens the company’s focus on QSP, ensuring continued innovation and latest expertise.
New publication: Pharmacometric analyses distinguished the circadian rhythm, placebo response andnepadutant treatment response for duration of crying and fussing in infants with colic.
New publication: PBPK analysis supports dose selection for a sustained-release 5-FC for improved CM treatment in HIV patients
Pharmetheus passes 100 employees and moves to new office in central Uppsala
Pharmetheus AB has reached a capacity milestone with more than one hundred persons on the team, and relocates to new headquarters next to Uppsala Central Station, a strategic move to accommodate the growing need of its services, driving the expansion of the team.
CAR-T cell therapy is part of the next generation of immuno-oncology treatment
It was Anna’s passion and expertise in these novel therapeutic modalities like CAR-T cells that led her to her current position at Pharmetheus. She can be considered one of the few experts in the field of CAR-T cell modeling, and her review paper “Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling” was one of the most downloaded papers last year.